CG Oncology, Inc. 8-K — AI Bull & Bear Analysis

The 8-K filing confirms that CG Oncology has maintained its corporate governance structure through the 2026 annual meeting, with all proposals passing. While the results are nominally positive, the tension between the high percentage of 'for' votes and the significant volume of non-participating shares creates a complex picture of investor sentiment. The company now moves forward with a refreshed board and a mandate for annual executive compensation reviews, though the market will likely remain focused on the company's ability to fund its operations without further diluting shareholders.